Walter Stadler

Summary

Affiliation: University of Chicago
Country: USA

Publications

  1. ncbi request reprint Gemcitabine doublets in advanced urothelial cancer
    Walter M Stadler
    Section Hematology Oncology, Cancer Research Center, University of Chicago, Chicago, IL 60637, USA
    Semin Oncol 29:15-9. 2002
  2. ncbi request reprint Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer
    Walter M Stadler
    University of Chicago, Illinois 60637, USA
    J Urol 170:1141-5. 2003
  3. ncbi request reprint Therapeutic options for variant renal cancer: a true orphan disease
    Walter M Stadler
    Section Hematology Oncology, Department of Medicine, University of Chicago, Chicago, Illinois 60036, USA
    Clin Cancer Res 10:6393S-6S. 2004
  4. ncbi request reprint Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901
    Walter M Stadler
    University of Chicago, Section of Hematology Oncology, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637, USA
    J Clin Oncol 23:3726-32. 2005
  5. ncbi request reprint Perioperative chemotherapy in locally advanced bladder cancer
    Walter M Stadler
    Department of Medicine, Section of Hematology Oncology and Urology, University of Chicago, Chicago, IL 60637, USA
    Lancet 361:1922-3. 2003
  6. ncbi request reprint Targeted agents for the treatment of advanced renal cell carcinoma
    Walter M Stadler
    Division of Genitourinary Oncology, Section of Hematology Oncology, Department of Medicine and Cancer Research Center, University of Chicago, Chicago, Illinois 60637, USA
    Cancer 104:2323-33. 2005
  7. ncbi request reprint Chromosomes, hypoxia, angiogenesis, and trial design: a brief history of renal cancer drug development
    Walter Stadler
    Department of Medicine, Sections of Hematology Oncology and Urology, University of Chicago, Chicago, IL 60637, USA
    Clin Cancer Res 13:1630-3. 2007
  8. ncbi request reprint Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer
    Walter M Stadler
    University of Chicago, Department of Medicine, 5841 S Maryland, MC2115, Chicago, Illinois 60637, USA
    Urol Oncol 7:153-7. 2002
  9. ncbi request reprint A phase II study of depsipeptide in refractory metastatic renal cell cancer
    Walter M Stadler
    Department of Medicine, University of Chicago, IL 60637 1470, USA
    Clin Genitourin Cancer 5:57-60. 2006
  10. ncbi request reprint A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma
    Walter M Stadler
    Department of Medicine, Section of Hematology Oncology and Urology, University of Chicago, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637, USA
    Cancer Chemother Pharmacol 61:689-94. 2008

Detail Information

Publications89

  1. ncbi request reprint Gemcitabine doublets in advanced urothelial cancer
    Walter M Stadler
    Section Hematology Oncology, Cancer Research Center, University of Chicago, Chicago, IL 60637, USA
    Semin Oncol 29:15-9. 2002
    ..Combinations with targeted therapeutic agents such as the epidermal growth factor receptor inhibitors and trastuzumab have great potential, but the clinical studies have not yet been completed...
  2. ncbi request reprint Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer
    Walter M Stadler
    University of Chicago, Illinois 60637, USA
    J Urol 170:1141-5. 2003
    ..To identify patient subgroups most likely to benefit and compare survival to that in previously described patient series long-term survival as a function of known and suspected prognostic variables was determined...
  3. ncbi request reprint Therapeutic options for variant renal cancer: a true orphan disease
    Walter M Stadler
    Section Hematology Oncology, Department of Medicine, University of Chicago, Chicago, Illinois 60036, USA
    Clin Cancer Res 10:6393S-6S. 2004
    ..Such a registry could provide support for a more formal multi-institutional study investigating a specific drug or regimen...
  4. ncbi request reprint Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901
    Walter M Stadler
    University of Chicago, Section of Hematology Oncology, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637, USA
    J Clin Oncol 23:3726-32. 2005
    ..To assess the disease-stabilizing activity of carboxyaminoimidazole (CAI) in patients with metastatic renal cell cancer (RCC) using a randomized discontinuation trial (RDT) design...
  5. ncbi request reprint Perioperative chemotherapy in locally advanced bladder cancer
    Walter M Stadler
    Department of Medicine, Section of Hematology Oncology and Urology, University of Chicago, Chicago, IL 60637, USA
    Lancet 361:1922-3. 2003
  6. ncbi request reprint Targeted agents for the treatment of advanced renal cell carcinoma
    Walter M Stadler
    Division of Genitourinary Oncology, Section of Hematology Oncology, Department of Medicine and Cancer Research Center, University of Chicago, Chicago, Illinois 60637, USA
    Cancer 104:2323-33. 2005
    ....
  7. ncbi request reprint Chromosomes, hypoxia, angiogenesis, and trial design: a brief history of renal cancer drug development
    Walter Stadler
    Department of Medicine, Sections of Hematology Oncology and Urology, University of Chicago, Chicago, IL 60637, USA
    Clin Cancer Res 13:1630-3. 2007
  8. ncbi request reprint Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer
    Walter M Stadler
    University of Chicago, Department of Medicine, 5841 S Maryland, MC2115, Chicago, Illinois 60637, USA
    Urol Oncol 7:153-7. 2002
    ..To assess long-term survival and prognostic indicators of survival in patients with advanced urothelial cancer treated with gemcitabine and cisplatin...
  9. ncbi request reprint A phase II study of depsipeptide in refractory metastatic renal cell cancer
    Walter M Stadler
    Department of Medicine, University of Chicago, IL 60637 1470, USA
    Clin Genitourin Cancer 5:57-60. 2006
    ..Therapeutic options for renal cell cancer are inadequate. Depsipeptide is a histone deacetylase inhibitor with promising preclinical and early clinical activity...
  10. ncbi request reprint A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma
    Walter M Stadler
    Department of Medicine, Section of Hematology Oncology and Urology, University of Chicago, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637, USA
    Cancer Chemother Pharmacol 61:689-94. 2008
    ..GTI-2040 is a 20-mer phosphorothioate oligonucleotide complimentary to the R2 component of ribonucleotide reductase that has activity in renal cancer models...
  11. ncbi request reprint Development of growth inhibitory agents in urological and other malignancies
    Walter M Stadler
    University of Chicago, Departments of Medicine and Surgery, Sections Hematology Oncology and Urology, Chicago, IL 60637, USA
    BJU Int 98:497-502. 2006
  12. ncbi request reprint A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008
    Walter M Stadler
    Section of Hematology Oncology, Department of Medicine, University of Chicago Medical Center, Chicago, Illinois 60637, USA
    Cancer 107:1273-9. 2006
    ..The objective of this study was to verify previous reports of activity with gemcitabine plus a fluoropyrimidine in patients with metastatic renal cell cancer in a multiinstitutional setting...
  13. doi request reprint Other paradigms: randomized discontinuation trial design
    Walter Stadler
    From the Departments of Medicine and Surgery, Sections of Hematology Oncology and Urology, University of Chicago, Chicago, IL, USA
    Cancer J 15:431-4. 2009
    ....
  14. ncbi request reprint The randomized discontinuation trial: a phase II design to assess growth-inhibitory agents
    Walter M Stadler
    Section of Hematology Oncology, University of Chicago, 5841 South Maryland, MC2115, Chicago, IL 60637, USA
    Mol Cancer Ther 6:1180-5. 2007
    ....
  15. ncbi request reprint A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer
    Walter M Stadler
    University of Chicago Phase II Consortium, University of Chicago, Section of Hematology Oncology, Chicago, Illinois 60637, USA
    Clin Cancer Res 10:3365-70. 2004
    ..In vitro assessment of SU5416 on PSA secretion was assessed in the LNCaP cell line. Baseline serum basic fibroblast growth factor and plasma vascular endothelial growth factor (VEGF) were explored as prognostic factors...
  16. pmc Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma
    Olwen M Hahn
    University of Chicago, Chicago, IL 60637, USA
    J Clin Oncol 26:4572-8. 2008
    ..Sorafenib is an antiangiogenic agent with activity in renal cancer. We conducted a randomized trial to investigate dynamic contrast magnetic resonance imaging (DCE-MRI) as a pharmacodynamic biomarker...
  17. pmc Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia
    Halla S Nimeiri
    University of Chicago, Chicago, IL 60637, USA
    Gynecol Oncol 110:49-55. 2008
    ..The objectives of this phase II trial were to assess the activity and tolerability of the combination of bevacizumab and erlotinib in patients with recurrent ovarian, primary peritoneal or fallopian tube cancer...
  18. ncbi request reprint Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma
    Amy C Peterson
    Department of Medicine, Section of Hematology Oncology, University of Chicago Cancer Research Center, Chicago, Illinois, USA
    Clin Cancer Res 10:4048-54. 2004
    ..A Phase II study of SU5416, a preferential inhibitor of Flk-1, was carried out in patients with metastatic melanoma to determine clinical response, tolerability, and changes in tumor vascular perfusion...
  19. ncbi request reprint A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer
    Andrew Artz
    Department of Medicine, Section of Hematology Oncology, University of Chicago, Pritzker School of Medicine, Chicago, Illinois 60637 1470, USA
    Am J Clin Oncol 28:109-13. 2005
    ....
  20. doi request reprint Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America
    Walter M Stadler
    Department of Medicine, University of Chicago Medical Center, Chicago, Illinois
    Cancer 116:1272-80. 2010
    ..The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) program made sorafenib available to patients with advanced renal cell carcinoma (RCC) before regulatory approval...
  21. ncbi request reprint Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer
    James O Jin
    Section of Hematology Oncology, University of Chicago, IL 60637, USA
    Clin Genitourin Cancer 5:150-4. 2006
    ..Despite the general acceptance of gemcitabine/cisplatin in metastatic bladder cancer, its role and tolerability in the adjuvant setting, in which renal insufficiency is common, is unclear...
  22. ncbi request reprint A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia
    Gonzalo Gomez-Abuin
    Department of Medicine, University of Chicago, Chicago, IL 60637, USA
    Invest New Drugs 25:181-5. 2007
    ....
  23. ncbi request reprint Multiple reference tissue method for contrast agent arterial input function estimation
    Cheng Yang
    Department of Medicine, University of Chicago, Chicago, Illinois, USA
    Magn Reson Med 58:1266-75. 2007
    ..This method is applicable to general kinetic models in DCE-MRI, as well as other CE imaging modalities...
  24. ncbi request reprint Angiogenesis inhibitors in genitourinary cancers
    Walter Stadler
    Department of Medicine Surgery, Sections of Hematology, Oncology and Urology, University of Chicago, 5841 S Maryland, MC2115, 60637, Chicago, IL, USA
    Crit Rev Oncol Hematol 46:S41-7. 2003
    ....
  25. ncbi request reprint Developing drugs that do not cause tumor regression
    Walter Stadler
    University of Chicago, USA
    Clin Adv Hematol Oncol 1:654-5. 2003
  26. ncbi request reprint A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma
    Amy C Peterson
    Department of Medicine, Section of Hematology Oncology, The University of Chicago, USA
    Invest New Drugs 24:141-9. 2006
    ..We combined different doses of Bryostatin-1 with IL-2 to determine effects on clinical response rate and T cell phenotype in patients with advanced kidney cancer...
  27. doi request reprint Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study
    David J Vaughn
    Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Cancer 115:4110-7. 2009
    ..The activity and safety of vinflunine was evaluated in patients with locally advanced or metastatic urothelial carcinoma (UC) who developed disease progression within 12 months of platinum-containing chemotherapy...
  28. ncbi request reprint Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer
    Theodore G Karrison
    Department of Health Studies, University of Chicago, Chicago, IL 60637, USA
    J Natl Cancer Inst 99:1455-61. 2007
    ..This design may efficiently eliminate truly ineffective therapy but may not reliably indicate whether subsequent phase III testing is warranted...
  29. ncbi request reprint Gene expression profiling of renal medullary carcinoma: potential clinical relevance
    Ximing J Yang
    Department of Pathology, The University of Chicago, Chicago, Illinois, USA
    Cancer 100:976-85. 2004
    ..To the authors' knowledge, very little is known to date regarding the underlying molecular genetics of this tumor, and no effective therapy has been established...
  30. ncbi request reprint Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time
    Milica Medved
    Department of Radiology, The University of Chicago, Chicago, Illinois, USA
    J Magn Reson Imaging 20:122-8. 2004
    ..To evaluate variability of a simplified method for measuring semiquantitative DCE-MRI parameters in patients with cancer and to explore effects of treatment with a putative anti-angiogenic compound...
  31. ncbi request reprint Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
    Michael B Atkins
    Department of Medicine, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, E Campus, Kirstein 158, Boston, MA 02215, USA
    J Clin Oncol 22:909-18. 2004
    ..To evaluate the efficacy, safety, and pharmacokinetics of multiple doses of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma (RCC)...
  32. ncbi request reprint Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study
    Nancy B Davis
    Section of Hematology Oncology, University of Chicago Medical Center, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637, USA
    J Clin Oncol 22:115-9. 2004
    ..Determine response rate, time to disease progression, and toxicity of the proteasome inhibitor PS-341 in patients with stage IV renal cell cancer...
  33. ncbi request reprint Angiogenesis inhibition in non-clear cell renal cancer
    Walter Stadler
    Department of Medicine, Section of Hematology Oncology, University of Chicago Medical Center, Chicago, IL, USA
    Clin Adv Hematol Oncol 6:507-9. 2008
  34. pmc Reproducibility assessment of a multiple reference tissue method for quantitative dynamic contrast enhanced-MRI analysis
    Cheng Yang
    Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA
    Magn Reson Med 61:851-9. 2009
    ..The MRTM can be applied to DCE-MRI studies of bone metastases from prostate cancers to provide an AIF from which reproducible quantitative DCE-MRI parameters can be derived, thus help standardize DCE-MRI studies in cancer patients...
  35. ncbi request reprint Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
    Mark J Ratain
    University of Chicago, Chicago, IL 60637, USA
    J Clin Oncol 24:2505-12. 2006
    ..This phase II randomized discontinuation trial evaluated the effects of sorafenib (BAY 43-9006), an oral multikinase inhibitor targeting the tumor and vasculature, on tumor growth in patients with metastatic renal cell carcinoma...
  36. ncbi request reprint A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma
    Apurva A Desai
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA
    Cancer 95:1629-36. 2002
    ....
  37. ncbi request reprint A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma
    Edwin M Posadas
    University of Chicago Phase II Consortium, Section of Hematology Oncology, Chicago, Illinois 60637, USA
    Cancer Biol Ther 6:490-3. 2007
    ..Suggestion of activity in renal cell carcinoma (RCC) has been seen in early clinical studies...
  38. ncbi request reprint A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma
    Christopher W Ryan
    Department of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, Illinois, USA
    Cancer 94:2602-9. 2002
    ....
  39. doi request reprint An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease
    Joseph K Salama
    Department of Radiation and Cellular Oncology, The University of Chicago, Chicago, Illinois 60637, USA
    Clin Cancer Res 14:5255-9. 2008
    ..We investigated whether cancer patients with limited sites of metastatic disease (oligometastasis) who failed standard therapies could be identified and safely treated at one to five known sites of low-volume disease with radiotherapy...
  40. pmc Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment
    Michael L Maitland
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA
    Clin Cancer Res 15:6250-7. 2009
    ..This prospective, single-center, cohort study characterized ambulatory blood pressure monitoring as an early pharmacodynamic biomarker of VEGF signaling pathway inhibition by sorafenib...
  41. ncbi request reprint Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents
    Apurva A Desai
    Section of Hematology Oncology, Department of Medicine, The University of Chicago, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637, USA
    Curr Oncol Rep 7:116-22. 2005
    ....
  42. pmc Recommended changes to oncology clinical trial design: revolution or evolution?
    Mark J Ratain
    University of Chicago, Chicago, IL, USA
    Eur J Cancer 44:8-11. 2008
  43. doi request reprint Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging
    Aytekin Oto
    Department of Radiology, University of Chicago, 5841 S Maryland Ave, MC 2026, Chicago, IL 60637, USA
    Radiology 257:715-23. 2010
    ....
  44. doi request reprint Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial
    Thomas W Flaig
    Department of Medicine, University of Colorado Health Science Center, Mail Stop 8117, P O Box 6511, Aurora, CO 80045 0511, USA
    J Clin Oncol 26:1532-6. 2008
    ..Southwest Oncology Group (SWOG) study 9921 is a randomized, phase III, intergroup study to define the role of adjuvant chemotherapy in patients with high-risk prostate cancer...
  45. pmc Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy
    Stanley L Liauw
    Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    Int J Radiat Oncol Biol Phys 77:125-30. 2010
    ..The present study reviewed the outcomes of intermediate- and high-risk men treated with RT and short-term ADT...
  46. pmc Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: a prospective cohort study
    William Dale
    Department of Medicine, Section of Geriatrics and Palliative Medicine, University of Chicago, Chicago, IL 60637, USA
    J Clin Oncol 27:1557-63. 2009
    ..We tested the hypothesis that elevated cancer anxiety leads to earlier ADT initiation for BCR in older men...
  47. ncbi request reprint Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck
    Ezra E W Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637 1470, USA
    J Clin Oncol 21:1980-7. 2003
    ..ZD1839 is an orally active, selective EGFR tyrosine kinase inhibitor. This phase II study sought to explore the activity, toxicity, and pharmacodynamics of ZD1839 in SCCHN...
  48. ncbi request reprint Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer
    Hedy L Kindler
    Section of Hematology Oncology, University of Chicago Medical Center, IL 60637, USA
    J Clin Oncol 23:8033-40. 2005
    ..The objectives of this phase II study were to assess the response rate and overall survival of pancreatic cancer patients who received gemcitabine with the recombinant humanized anti-VEGF monoclonal antibody bevacizumab...
  49. pmc FYN is overexpressed in human prostate cancer
    Edwin M Posadas
    Section of Hematology Oncology, Department of Medicine, University of Chicago, IL, USA
    BJU Int 103:171-7. 2009
    ....
  50. ncbi request reprint A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma
    Nicholas J Vogelzang
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA
    Cancer 100:65-71. 2004
    ....
  51. ncbi request reprint Sorafenib
    Olwen Hahn
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Illinois 60637, USA
    Curr Opin Oncol 18:615-21. 2006
    ..Sorafenib is an oral, multikinase inhibitor that was recently approved for use in metastatic renal cancer. It is currently undergoing investigation in locally advanced renal cancer and in other tumor types...
  52. doi request reprint Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma
    Kathryn A Bylow
    Department of Medicine, Section of Hematology Oncology, University of Chicago, IL, USA
    Clin Genitourin Cancer 7:39-42. 2009
    ..Cytotoxic chemotherapy has not been well investigated in non-clear-cell renal cell carcinoma (RCC). A phase II study was thus conducted to assess the efficacy of carboplatin and paclitaxel in such patients...
  53. ncbi request reprint Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review
    Kathryn Bylow
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA
    Cancer 110:2604-13. 2007
    ....
  54. ncbi request reprint Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: results of a single- institution phase II trial
    Blase N Polite
    Section of Hematology Oncology, Department of Medicine, University of Chicago, IL 60637, USA
    Clin Genitourin Cancer 4:275-80. 2006
    ..Imatinib mesylate inhibits PDGF-mediated signal transduction and might thus have antiangiogenic activity as well...
  55. doi request reprint Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer
    Matthew I Milowsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 102:1339-44. 2008
    ..Ongoing research will focus on individualized patient care, with biomarkers to predict a pathological complete response and the development of novel targeted therapies...
  56. ncbi request reprint Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity
    Brian I Rini
    Department of Medicine, Section of Hematology Oncology, The University of Chicago, 5841 S Maryland Avenue, Chicago, IL 60637, U S A
    J Immunother 25:269-77. 2002
    ....
  57. ncbi request reprint Thalidomide-associated deep vein thrombosis and pulmonary embolism
    Charles L Bennett
    Midwest Center for Health Services and Policy Research, Chicago VA Healthcare System Lakeside Division, 400 East Ontario, Room 205, Chicago, IL 60611, USA
    Am J Med 113:603-6. 2002
  58. ncbi request reprint New trial designs to assess antitumor and antiproliferative agents in prostate cancer
    Walter Stadler
    Section Hematology Oncology and Urology, Genitourinary Cancer Program, UC Cancer Research Center, University of Chicago, IL 60637, USA
    Invest New Drugs 20:201-8. 2002
    ..Use of such designs as well as surrogate marker validation will likely be required to efficiently choose appropriate agents for definitive study in the phase III setting...
  59. ncbi request reprint Androgen ablation adjuvant to postprostatectomy radiotherapy: complication-adjusted number needed to treat analysis
    Ashesh B Jani
    Department of Radiation and Cellular Oncology, University of Chicago Hospitals, Chicago, Illinois 60637, USA
    Urology 64:976-81. 2004
    ..To quantify the benefits and harm of androgen ablation (AA) adjuvant to radiotherapy in the postprostatectomy setting. AA is commonly used in the management of prostate cancer...
  60. pmc Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy
    Kathryn Bylow
    Department of Medicine, Section of Hematology Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
    Urology 72:422-7. 2008
    ..Men experience a decrease in lean muscle mass and strength during the first year of androgen deprivation therapy (ADT). The prevalence of falls and physical and functional impairment in this population have not been well described...
  61. doi request reprint The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer
    David Knight
    Section of Hematology Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois, USA
    Prostate 69:142-8. 2009
    ..One vaccination strategy that is being pursued in the clinic utilizes peptide-pulsed peripheral blood mononuclear cells (PBMC) + IL-12...
  62. ncbi request reprint Prognostic factors in localized renal cell cancer
    David A Knight
    Section of Hematology Oncology, Department of Medicine, University of Chicago Medical Center, The Pritzker School of Medicine, Chicago, IL 60637 1470, USA
    BJU Int 99:1212-6. 2007
  63. pmc A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer
    Richard T Lee
    Department of Medicine, Section of Hematology Oncology, The University of Chicago, IL 60637, USA
    Clin Genitourin Cancer 6:21-4. 2008
    ..SB-715992 is a new agent that inhibits the function of a mitotic kinesin known as kinesin spindle protein and leads to cell death...
  64. ncbi request reprint The role of systemic chemotherapy in the treatment of kidney cancer
    Christopher M George
    Section of Hematology Oncology, University of Chicago Medical Center, 5841 South Maryland Ave, MC 2115, Chicago, IL 60637 1470, USA
    Cancer Treat Res 116:173-82. 2003
    ..Nonetheless, low level activity of several nucleoside analogues and the elucidation of critical molecular pathways and targets in this disease, such as the angiogenic pathway, provide hope that important advances can and will be made...
  65. ncbi request reprint Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study
    Brian I Rini
    Department of Medicine, University of California San Francisco Cancer Center, San Francisco, California, USA
    Biol Blood Marrow Transplant 12:778-85. 2006
    ..A graft-versus-tumor effect was not observed in this study despite acute and chronic GVHD, thus highlighting the need for further understanding of this approach. Allogeneic SCT remains investigational in RCC...
  66. ncbi request reprint Estimating the arterial input function using two reference tissues in dynamic contrast-enhanced MRI studies: fundamental concepts and simulations
    Cheng Yang
    Department of Medicine, University of Chicago, Illinois 60637, USA
    Magn Reson Med 52:1110-7. 2004
    ..These factors will produce errors in the AIF estimate. Simulation studies show that despite the two error sources, the double-reference-tissue method provides reliable estimates of the AIF...
  67. ncbi request reprint Metastasis suppressor genes: signal transduction, cross-talk and the potential for modulating the behavior of metastatic cells
    Jonathan C Berger
    Pritzker School of Medicine, University of Chicago, Chicago, IL, USA
    Anticancer Drugs 15:559-68. 2004
    ....
  68. ncbi request reprint Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site
    Eric C Kauffman
    Section of Urology, Department of Surgery, University of Chicago Comprehensive Cancer Research Center, Illinois 60637, USA
    J Urol 169:1122-33. 2003
    ..We also reviewed the definition, identification and characterization of metastasis suppressor genes, and discuss their evolving role in regulating this step...
  69. doi request reprint Renal medullary-like carcinoma in an adult without sickle cell hemoglobinopathy
    Peter H O'Donnell
    Section of Hematology Oncology and Department of Medicine, The University of Chicago, 5841 South Maryland Avenue, MC 2115, Chicago, IL 60637, USA
    Nat Rev Urol 7:110-4. 2010
    ..A 42-year-old white man with no significant prior medical history presented with macroscopic hematuria of 2 months' duration. His family history was notable for a maternal grandfather with kidney cancer...
  70. pmc Comparison of quantitative parameters in cervix cancer measured by dynamic contrast-enhanced MRI and CT
    Cheng Yang
    Department of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, Illinois, USA
    Magn Reson Med 63:1601-9. 2010
    ..Close correlation of quantitative parameters derived from two independent imaging modalities suggests both are measuring similar tumor physiologic variables...
  71. doi request reprint Adjuvant chemotherapy in lymph node positive bladder cancer
    Ofer N Gofrit
    Department of Surgery, Section of Urology, and the Sections of Hematology Oncology and Biostatistics, University of Chicago, Chicago, IL 60637, USA
    Urol Oncol 27:160-4. 2009
    ..In this retrospective study, we compare the outcomes of patients with microscopic lymph node positive bladder cancer (pN1 or pN2) treated with radical cystectomy followed by adjuvant chemotherapy and those who declined chemotherapy...
  72. ncbi request reprint Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)
    Eric J Small
    UCSF Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, Room A 718, San Francisco, CA 94115, USA
    J Clin Oncol 22:1025-33. 2004
    ..Thereafter, adrenal androgen ablation with agents such as ketoconazole (K) is commonly utilized. The therapeutic effect of AAWD alone was compared with simultaneous AAWD and K therapy...
  73. ncbi request reprint A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer
    Donald S Kaufman
    Massachusetts General Hospital, Boston, MA, USA
    Urol Oncol 22:393-7. 2004
    ..Insufficient patients with poor renal function or prior therapy were accrued to reach conclusions regarding its utility in these subgroups...
  74. ncbi request reprint Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results
    Brian I Rini
    University of California San Francisco, Comprehensive Cancer Center, San Francisco, CA 94115, USA
    J Clin Oncol 20:2017-24. 2002
    ..To evaluate the feasibility and safety of nonmyeloablative allogeneic stem-cell transplantation in patients with metastatic renal cell cancer (RCC) and to evaluate efficacy with respect to engraftment and tumor regression...
  75. doi request reprint Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
    Brian I Rini
    Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Desk R35, Cleveland, OH 44195, USA
    J Clin Oncol 26:3743-8. 2008
    ..To assess the safety and efficacy of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma (mRCC) and explore biomarkers for sunitinib response...
  76. ncbi request reprint Sorafenib in advanced clear-cell renal-cell carcinoma
    Bernard Escudier
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    N Engl J Med 356:125-34. 2007
    ..We conducted a phase 3, randomized, double-blind, placebo-controlled trial of sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, in patients with advanced clear-cell renal-cell carcinoma...
  77. ncbi request reprint Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)
    Charles J Ryan
    Urologic Oncology Program, UCSF Comprehensive Cancer Center, 1600 Divisadero 3rd Floor, San Francisco, CA, USA
    Invest New Drugs 25:445-51. 2007
    ..While further study is indicated, careful attention must be paid to the novel toxicities of this agent with prolonged dosing...
  78. ncbi request reprint Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid
    Christopher W Ryan
    Division of Hematology and Medical Oncology, Oregon Health and Science University, 3303 SW Bond Avenue, Portland, OR 97239, USA
    BJU Int 100:70-5. 2007
    ....
  79. ncbi request reprint A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases
    Primo N Lara
    University of California Davis Cancer Center and the University of California Davis School of Medicine, Sacramento, California 95817, USA
    Clin Cancer Res 12:1556-63. 2006
    ..Serial serum and urine specimens were collected to assess for markers of bone metabolism...
  80. ncbi request reprint New targets, therapies, and toxicities: lessons to be learned
    Walter M Stadler
    J Clin Oncol 24:4-5. 2006
  81. ncbi request reprint Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?
    Walter M Stadler
    J Clin Oncol 23:8124-5; author reply 8125-6. 2005
  82. ncbi request reprint A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy
    Nancy B Davis
    Division of Neoplastic Diseases and Related Disorders, Medical College of Wisconsin, Milwaukee, WI, USA
    BJU Int 96:787-90. 2005
    ..To determine the prostate-specific antigen (PSA) response and time to PSA or radiographic progression in men with prostate cancer refractory to bicalutamide and/or flutamide therapy...
  83. ncbi request reprint A Phase II study of oxaliplatin in urothelial cancer
    Eric Winquist
    Princess Margaret Hospital Phase II Consortium, London Regional Cancer Centre, London, Ontario, Canada
    Urol Oncol 23:150-4. 2005
    ..To assess the antitumor activity of oxaliplatin, a third generation platinum derivative with a 1,2-diaminocyclohexane (DACH) carrier ligand, in patients with metastatic transitional cell carcinoma of the bladder (TCC)...
  84. ncbi request reprint A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer
    Christopher W Ryan
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR 97239 3098, USA
    BJU Int 95:963-8. 2005
    ....
  85. ncbi request reprint Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma
    Michael E Burczynski
    Molecular Profiling and Biomarker Discovery, Wyeth Research, 1 Burtt Road, Andover, MA 01810, USA
    Clin Cancer Res 11:1181-9. 2005
    ....
  86. doi request reprint Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma
    Eric Jonasch
    Department of Genitourinary Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 113:72-7. 2008
    ..The purpose of the current study was to evaluate the activity and safety of TLF in patients with refractory metastatic renal cell carcinoma (RCC)...
  87. doi request reprint Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy
    Lance K Lassiter
    Matthews Hematology Oncology Associates, Matthews, NC, USA
    Clin Genitourin Cancer 6:31-5. 2008
    ..We report the results of a multiinstitutional, open-label, 2-stage, phase II study that further evaluates oral piritrexim in patients with urothelial carcinoma and who proved nonresponsive to standard chemotherapy...
  88. ncbi request reprint Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668
    Darren W Davis
    Department of Cancer Biology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 11:678-89. 2005
    ....
  89. ncbi request reprint A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation
    Supriya G Mohile
    Department of Medicine Oncology, Columbia Presbyterian Medical Center, New York, New York, USA
    Cancer 109:802-10. 2007
    ....